Product Information
TREMFYA 200 MG/2 ML PEN is a brand product labeled by Janssen Biotech, Inc., priced at $7321.6557 per ML under NDC 57894065102. Its NADAC has been published 42 times since Dec 17, 2025.
Strength
200 mg/2mL
Manufacturer
Janssen Biotech, Inc.NDC
57894065102
Classification
Brand
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
GUSELKUMABApproval Type
Biologic (BLA)
FDA Application
BLA761061On Market Since
9/11/2024
Pharmacological Classes
Price Statistics
The NADAC for TREMFYA 200 MG/2 ML PEN has been published 42 times since Dec 17, 2025, and over the history we have for it it has risen 4.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $7321.6557 per ML |
|---|---|
| All-time high | $7349.6703 (Jul 15, 2026) |
| All-time low | $6999.6860 (Dec 17, 2025) |
| 52-week high | $7349.6703 |
| 52-week low | $6999.6860 |
| Median price | $7349.6703 |
| Average price | $7274.2324 |
| Largest weekly change | +5.0% (Feb 11, 2026) |
| Weeks tracked | 42 |
| Tracking since | Dec 17, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the guselkumab market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Janssen Biotech, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
guselkumab market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Interleukin-23 Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TREMFYA 200 MG/2 ML PEN?
The current National Average Drug Acquisition Cost (NADAC) for TREMFYA 200 MG/2 ML PEN, manufactured by Janssen Biotech, Inc., is $7321.6557 per ML (NDC 57894065102), effective Sep 30, 2026.
How has the price of TREMFYA 200 MG/2 ML PEN changed over time?
Over the history we have for it, the NADAC for TREMFYA 200 MG/2 ML PEN has risen 4.6%. It has been tracked across 42 weekly CMS publications since Dec 17, 2025.
What are the highest and lowest recorded NADAC prices for TREMFYA 200 MG/2 ML PEN?
Since Dec 17, 2025, the NADAC for TREMFYA 200 MG/2 ML PEN has ranged from a low of $6999.6860 (Dec 17, 2025) to a high of $7349.6703 (Jul 15, 2026), with a median of $7349.6703 per ML.
Are there cheaper alternatives to TREMFYA 200 MG/2 ML PEN?
No other NADAC-published product currently shares the active ingredient and strength of TREMFYA 200 MG/2 ML PEN in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TREMFYA 200 MG/2 ML PEN?
TREMFYA 200 MG/2 ML PEN (NDC 57894065102) is labeled by Janssen Biotech, Inc., and CMS classifies it as a brand product.